chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Chills, Fatigue, Lymph node pain, Pain
Clinical narrative: low on energy; pain in the lymph node in the left armpit; fatigue; general body pain; chills; vaccination site pain; This is a spontaneous report received from a contactable consumer, the patient. A 44-year-old non pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730), via an unspecified route of administration in the left arm on 26Mar2021 at 10:30 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history included bipolar disorder. Concomitant medications included lamotrigine (MANUFACTURER UNKNOWN), quetiapine fumarate (SEROQUEL), clonazepam (MANUFACTURER UNKNOWN), fexofenadine hydrochloride (ALLEGRA) and caffeine, paracetamol and ibuprofen (IBUPRO); all taken for unknown indications and from unknown dates. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199), via an unspecified route of administration in the left arm on 03Mar2021 at 08:00 (at the age of 44-years). On 26Mar2021, the patient experienced the event pain at the injection point in the left arm. On 27Mar2021 at 11:00, the patient experienced fatigue, body aches, and chills and on 28Mar, 2021 at 08:00, the patient experienced pain in the lymph node in her left armpit and the patient felt low on energy and bit achy. The persistent pain in the lymph node was the reason, the patient reported the event. Treatment was taken as a result of lymph node pain with ibuprofen 200mg. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the events vaccination site pain, fatigue, general body pain, chills, lymph node pain and energy decreased was not recovered. No follow-up attempts possible. No further information expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: low on energy; pain in the lymph node in the left armpit; fatigue; general body pain; chills; vaccination site pain; This is a spontaneous report received from a contactable consumer, the patient. A 44-year-old non pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730), via an unspecified route of administration in the left arm on 26Mar2021 at 10:30 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history included bipolar disorder. Concomitant medications included lamotrigine (MANUFACTURER UNKNOWN), quetiapine fumarate (SEROQUEL), clonazepam (MANUFACTURER UNKNOWN), fexofenadine hydrochloride (ALLEGRA) and caffeine, paracetamol and ibuprofen (IBUPRO); all taken for unknown indications and from unknown dates. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199), via an unspecified route of administration in the left arm on 03Mar2021 at 08:00 (at the age of 44-years). On 26Mar2021, the patient experienced the event pain at the injection point in the left arm. On 27Mar2021 at 11:00, the patient experienced fatigue, body aches, and chills and on 28Mar, 2021 at 08:00, the patient experienced pain in the lymph node in her left armpit and the patient felt low on energy and bit achy. The persistent pain in the lymph node was the reason, the patient reported the event. Treatment was taken as a result of lymph node pain with ibuprofen 200mg. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the events vaccination site pain, fatigue, general body pain, chills, lymph node pain and energy decreased was not recovered. No follow-up attempts possible. No further information expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Arthralgia, Chills, Cough, Fatigue
Clinical narrative: Headache; Chills; Fatigue; Cough; body ache; Fever; stomaache; muscle pain; wrist pain; ankle pain; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: Unknown) via an unspecified route of administration in the left arm on 27Mar2021 at 13:45 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included fluticasone furoate, vilanterol trifenatate (BREO ELLIPTA), salbutamol (ALBUTEROL) for unknown indication from unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 28Mar2021 at 01:30, the patient experienced headache, chills, fatigue, cough, body ache, fever, stomach ache, muscle pain, wrist and ankle pain. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event headache, chills, fatigue, cough, body ache, fever, stomach ache, muscle pain, wrist and ankle pain were not resolved at the time of this report. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Myalgia, Pain, Pyrexia
Clinical narrative: Headache; Chills; Fatigue; Cough; body ache; Fever; stomaache; muscle pain; wrist pain; ankle pain; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: Unknown) via an unspecified route of administration in the left arm on 27Mar2021 at 13:45 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included fluticasone furoate, vilanterol trifenatate (BREO ELLIPTA), salbutamol (ALBUTEROL) for unknown indication from unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 28Mar2021 at 01:30, the patient experienced headache, chills, fatigue, cough, body ache, fever, stomach ache, muscle pain, wrist and ankle pain. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event headache, chills, fatigue, cough, body ache, fever, stomach ache, muscle pain, wrist and ankle pain were not resolved at the time of this report. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Sex: F
Vaccine: COVID19
Symptoms: Therapeutic response unexpected
Clinical narrative: I have taken both of the Pfizer BioNtech COVID vaccines, and surprisingly it made me feel better; This is a spontaneous report based on the information received by Pfizer from BioNTech (Reference #24877) and a contactable consumer (patient). A non-pregnant female patient of an unspecified age has received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, Lot number: Unknown) via an unspecified site of administration and unknown date at single dose for covid-19 immunization. Patient medical history included triple negative breast cancer, human papilloma virus infection (HPV) from 2004 and carcinoma in situ from 2004, chemotherapy and radiation therapy. Patient undergone chemo and radiation for breast cancer which she truly believe is a result of the HPV virus. Patients concomitant medications were not reported. The patient previously took first dose of BNT62B2 (PFIZER-BIONTECH covid-19 vaccine, formulation: solution for injection, lot number: unknown) via an unspecified route of administration at single dose for covid-19 immunization. Patient reported that she was a patient with triple negative breast cancer with a history of HPV that was so severe in 2004 that It turned into carcinoma in situ. Patient have undergone chemo and radiation for breast cancer which she truly believes was a result of the HPV virus. It now appears that the cancer has recurred. Please note that she never drank, smoked, taken a single drug and had no genetic disposition to breast cancer, nor has any one in her family had breast cancer. That is why patient was convinced that her Breast Cancer was HPV driven, patient was fortunate to be treated by the world's foremost oncologist, but she was convinced that unless the HPV virus was taken into consideration in the medicine for my treatment, it will not work. She feels input from BioNtech could provide a ground-breaking dynamic to her treatment. Patient have taken both of the Pfizer BioNtech COVID vaccines, and surprisingly it made her feel better, her overall wellness related to cancer. This can be wishful thinking, but she doesn't think so. Patient read an article that you feel a Cancer Vaccine will be available in two years. She feels your research in regard to viruses is pivotal to managing cancer. She was the author of the Book which hit Best Seller list in 2005, and I am now working on the next version of the book. She collaborated with the world's most notable innovators who have changed the world including the co-creator of internet, so patient know how important innovation is especially to me now. Most importantly I have 3 children who need me. She was in the care of the best doctors in the world, but she truly believes that the HPV virus is a consideration in her health and treatment that must be controlled and is presently overlooked. This is the turning point for her, and she need help immediately. The outcome of event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Vaginal haemorrhage
Clinical narrative: vaginal bleeding; abdominal pain; This is a spontaneous report from a contactable consumer. A 21-years-old non-pregnant female patient received second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: 8733) via an unspecified route of administration in the left arm on 25Mar2021 at 09:00 (at an age of 21 years) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had seasonal allergies. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: 6205) via unspecified route of administration in the left arm on 04Mar2021 at 09:00 (at the age of 21-years-old) as a single dose for COVID-19 immunisation. Medications within two weeks of vaccination include medication for birth control. Prior to vaccination, the patient was not diagnosed for COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 27Mar2021 at 09:00, after two days of the second dose of vaccine, the patient experienced spotting with light vaginal bleeding. The patient reported that she had been on birth control for almost three years and had never spotted, and the patient always had period on the same exact day (which was not supposed to happen for another 10 days). The patient also experienced abdominal pain while it was happening. The patient did not receive any treatment for adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events light vaginal bleeding and abdominal pain were unknown.   No follow-up attempts possible. No further information expected.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Arthritis, Fatigue, Headache, Joint swelling
Clinical narrative: Fatigue; Headache; Joint pain; Knees inflamed and very red and hot to the touch; Both knees swollen; This is a spontaneous report from a contactable consumer, the patient. A 70 years-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6208) via an unspecified route of administration in the arm left on 12Mar2021at 10:45 (at the age of 70-years-old) as a single dose for COVID-19 Immunisation. Medical history was reported as high blood pressure, high cholesterol and hypothyroidism. Concomitant medications were reported as Fosamax (MANUFACTURER UNKNOWN), Norvasc (MANUFACTURER UNKNOWN), Trazodone (MANUFACTURER UNKNOWN), Efferox (MANUFACTURER UNKNOWN) and Synthroid (MANUFACTURER UNKNOWN) for an unknown indication from unspecified date. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6201) via an unspecified route of administration in the arm left on 19Feb2021 at 09:45 (at the age of 70-years-old) as a single dose for COVID-19 Immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient had not tested for COVID-19. The patient had allergies of penicillin and flu vaccine. On 12Mar2021 at 16:00, the patient experienced fatigue, headache, joint pain, both knees inflamed (joint inflammation) which was very red and hot to the touch with swollen (knee swelling). The patient did not receive treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fatigue, headache, joint pain, joint inflammation and knee swelling were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Supraclavicular lymph node swelling in arm of injection (right); This is a spontaneous report from a contactable consumer, the patient. A 27-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955) via an unspecified route of administration in the right arm on 18Mar2021 at 14:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included Ehlers Dalnos Syndrome type 3, postural orthostatic tachycardia syndrome, mast cell activation syndrome, hashimotos hypothyroidism, epilepsy, autoimmune chronic urticaria and angioedema on an unspecified date. The patient was on concomitant medications, names unspecified. The patient had known allergies to penicillin, cefazolin (MANAFACTURER UNKNOWN), hydrocodone; acitomenophen (VICODIN), and topiramate (MANAFACTURER UNKNOWN). The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient experienced supraclavicular lymph nodes enlarged on 24Mar2021. (Supraclavicular lymph node swelling in arm of injection (right) 6 days after vaccine). Treatment was not received for the events. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.   Clinical outcome of supraclavicular lymph nodes enlarged was not recovered.   No follow up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Confusional state, Fatigue, Lethargy, Nausea, Pain in extremity
Clinical narrative: Nauseous; lethargic; tired; sore arm; feel out of it; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 26Mar2021 at 14:30 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient was allergic to sulfur. Concomitant medication included magnesium (MANUFACTURER UNKNOWN) and zinc (MANUFACTURER UNKNOWN), ester C (MANUFACTURER UNKNOWN) and hydrochlorothiazide (MANUFACTURER UNKNOWN) for unspecified indications. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 27Mar2021 at 09:00, the patient experienced tiredness, lethargic, nauseous, sore arm/pain in arm, feel out of it/confusion state. The adverse events did not result in doctor or other healthcare professional office/clinic visit. The patient did not receive treatment for the reported events. The clinical outcome of tiredness, lethargic, nauseous, sore arm and feel out of it/confusion state was not recovered at this time of report.     Information about lot number cannot be obtained. No further information is expected.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia
Clinical narrative: Metal taste within minutes of the vaccine; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old not pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA vaccine; Lot number: Unknown), via an unspecified route of administration in left arm on 26Mar2021 at 14:30 (at age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic sinusitis. The patient did not have any known allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other medications within 2 weeks of vaccination. The patient was not diagnosed with Covid-19 prior to vaccination. The patient had not been tested for Covid-19 since the vaccination. On 26Mar2021 at 14:30, the patient had metal taste within minutes of the vaccine. The patient did not receive any therapeutic measure for the reported event. Adverse event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event metal taste within minutes of the vaccine was resolving at the time of report. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Diarrhoea
Clinical narrative: Increasingly worse stomach cramping; loose bowel movements; This is a spontaneous report from a contactable other health care professional. A 59-year-old female non pregnant patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: Unknown), via an unspecified route of administration on the right arm on 24Mar2021 at 12:00 (at the age of 59-year-old), as a first single dose for COVID-19 immunisation. Medical history included hashimotos thyroiditis. Concomitant medications included: Estradiol (VAGIFEM), Thyroid (ARMOUR THYROID) 120 mg, turmeric (MANUFACTURER UNKNOWN) and ginger (MANUFACTURER UNKNOWN) all for an unknown indication. The patient was allergic to celiacs sprue and latex. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 24Mar2021, at 18:00 the patient experienced increasingly worse stomach cramping with loose bowel movements. The patient did not receive any treatment for the reported events. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome for the events increasingly worse stomach cramping and loose bowel movements was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Heart rate, Heart rate increased, Vaccination site pain
Clinical narrative: increased heart rate within an hour of injection; Headache; injection site soreness; This is a spontaneous report from a contactable nurse, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA; Lot Number: ER8727), via an unspecified route of administration on 22Mar2021 at 09:30 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included restless leg syndrome. The patient did not have any allergies to food, medications, or other products. Concomitant medications included pramipexole dihydrochloride monohydrate (MIRAPEX), tramadol hydrochloride (ULTRAM), magnesium (MANUFACTURER UNKNOWN) and ibuprofen (MANUFACTURER UNKNOWN), all for unknown indications from unknown dates. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had not received any other vaccines within four weeks prior to the COVID vaccine. On 22Mar2021 at 09:45, the patient experienced headache for five days and injection site soreness for two days. At 10:30 (reported as within an hour of injection), the patient experienced increased heart rate. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events headache, vaccination site pain and heart rate increased. The clinical outcome of the event vaccination site pain was recovered on 24Mar2021; headache was recovered on 27Mar2021 and that of heart rate increased was recovered on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Lymphadenopathy, Muscular weakness, SARS-CoV-2 test
Clinical narrative: Swollen lymph node (left axillary); severe fatigue; muscle weakness; This is a spontaneous report from a contactable other health care professional, the patient. A 25-year-old female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL9264), via an unspecified route of administration in the left arm on 12Feb2021 (at the age of 25-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number:EN6206), via an unspecified route of administration in the left arm on 26Mar2021(at the age of 25-years-old); as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received amoxicillin (MANUFACTURER UNKNOWN) and metoclopramide (REGLAN); both on unknown dates for unspecified indications and experienced drug allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had tested for COVID-19. On an unspecified date in 2021, the patient experienced swollen lymph node (left axillary), severe fatigue and muscle weakness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient underwent lab test and procedures which included COVID test (nasal swab) on 26Mar2021 and tested negative. The clinical outcome of the events swollen lymph node, severe fatigue and muscle weakness were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Dizziness, Myalgia
Clinical narrative: Dizzy and lightheaded; Over 24 hours after vaccine, still sore in joints and muscles; Over 24 hours after vaccine, still sore in joints and muscles; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 26Mar2021 at 13:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included gluten allergy. The patient did not take any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 16:00, the patient felt sore in joints and muscles, dizzy and lightheaded. Over 24 hours after vaccine, the patient had still sore in joints and muscles, dizzy and lightheaded. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events dizzy, muscle soreness and soreness of joint. The clinical outcomes of the events dizzy, muscle soreness and soreness of joint were not recovered at the time of the report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Body temperature, Chills, Fatigue
Clinical narrative: loss of smell; Loss of taste; High fever; chills; sweats; Aches; fatigue; Swollen hard arm; Broke out with fever blisters nose mouth and lips; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727), via the unspecified route of administration in the right arm on 24Mar2021 at 13:30 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks of the COVID vaccination. The patient did not receive any medications within two weeks of the COVID-19 vaccination. On 25Mar2021 at 03:00, the patient experienced high fever, chills, sweats, aches, fatigue, swollen hard red arm for five-plus days, fever blisters in nose mouth and lips. On 28Mar2021 (day 5), the patient experienced the loss of smell and taste. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of the events high fever, chills, sweats, aches, fatigue was resolved in 48 hours on 27Mar2021; while the events of the swollen hard red arm, fever blisters, loss of smell and loss of taste was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Hyperhidrosis, Oral herpes, Pain, Peripheral swelling, Pyrexia
Clinical narrative: loss of smell; Loss of taste; High fever; chills; sweats; Aches; fatigue; Swollen hard arm; Broke out with fever blisters nose mouth and lips; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727), via the unspecified route of administration in the right arm on 24Mar2021 at 13:30 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks of the COVID vaccination. The patient did not receive any medications within two weeks of the COVID-19 vaccination. On 25Mar2021 at 03:00, the patient experienced high fever, chills, sweats, aches, fatigue, swollen hard red arm for five-plus days, fever blisters in nose mouth and lips. On 28Mar2021 (day 5), the patient experienced the loss of smell and taste. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of the events high fever, chills, sweats, aches, fatigue was resolved in 48 hours on 27Mar2021; while the events of the swollen hard red arm, fever blisters, loss of smell and loss of taste was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Musculoskeletal stiffness, Pain in extremity
Clinical narrative: Stiff arm; slightly sore/stiff arm; This is a spontaneous report from a non-contactable consumer, the patient. A 23-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 28March2021 at 10:15 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history reported. The patient did not have any allergies to food, medications, or other products. Concomitant medications were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 28Mar2021, the patient had only a slightly sore/stiff arm and the patient could still do her workouts without any problems. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The ice helped the patient with the pain and stiffness. The clinical outcomes of the events stiffness and pain in arm were recovering at the time of the report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Dysmenorrhoea, Fatigue, Headache, Menstrual disorder, Menstruation irregular
Clinical narrative: Two weeks early menstrual bleeding; Two weeks early menstrual bleeding, including clotting and mucus; two weeks early menstrual bleeding, including clotting and mucus accompanied by cramps; Fatigue; headache; body pain; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old-non-pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6208) via unspecified route of administration in the left arm on 13Mar2021 at 15:30 (at the age of 29-year-old) as a single dose for COVID-19 immunisation. The patient medical history included autoimmune disease. The patient was allergic to morphine, gluten and dairy. Concomitant medication included thyroid (ARMOUR THYROID) medication. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 23Mar2021, the patient underwent nasal swab test and tested negative for COVID-19. The patient was not diagnosed with COVID-19 prior to vaccination. On 14Mar2021, the patient experienced two weeks early menstrual bleeding, including clotting and mucus accompanied by cramps, fatigue, headache, and body pain lasted for more than 7 days. The patient did not receive treatment for the reported events. The events resulted in the doctor or other healthcare professional office/clinic visit. The clinical outcome of all events was unknown at this time of report.   No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, SARS-CoV-2 test
Clinical narrative: Two weeks early menstrual bleeding; Two weeks early menstrual bleeding, including clotting and mucus; two weeks early menstrual bleeding, including clotting and mucus accompanied by cramps; Fatigue; headache; body pain; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old-non-pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6208) via unspecified route of administration in the left arm on 13Mar2021 at 15:30 (at the age of 29-year-old) as a single dose for COVID-19 immunisation. The patient medical history included autoimmune disease. The patient was allergic to morphine, gluten and dairy. Concomitant medication included thyroid (ARMOUR THYROID) medication. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 23Mar2021, the patient underwent nasal swab test and tested negative for COVID-19. The patient was not diagnosed with COVID-19 prior to vaccination. On 14Mar2021, the patient experienced two weeks early menstrual bleeding, including clotting and mucus accompanied by cramps, fatigue, headache, and body pain lasted for more than 7 days. The patient did not receive treatment for the reported events. The events resulted in the doctor or other healthcare professional office/clinic visit. The clinical outcome of all events was unknown at this time of report.   No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Feeling of body temperature change, Headache, Myalgia
Clinical narrative: felt hot and cold through day; muscle aches; mild headache; fatigue; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the right arm on 24Mar2021 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive concomitant medications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the right arm on 01Mar2021 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not tested positive for COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 25Mar2021, the patient had experienced hot and cold feeling throughout the day, muscle aches, mild headache and fatigue. The clinical outcomes of the events feeling hot and cold, muscle aches, mild headache, and fatigue were recovered on an unknown date in Mar2021.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Musculoskeletal stiffness, Swelling
Clinical narrative: Swelling under left armpit into left breast area; shoulder blade area feels like a stiff neck sore to turn head to the left; shoulder and shoulder blade very sore on left side wrist up to neck back; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6199), via an unspecified route of administration in the left arm on 04Mar2021 at 19:30 (at the age of 52-years-old) and a second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EP7534), via an unspecified route of administration in the left arm on 25Mar2021 at 19:30 (at the age of 52-years-old), as single doses for COVID-19 immunisation. The patient had no medical history reported. The patient did not have any allergies to food, medications, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On an unknown date in Mar2021 at 05:00, the patient had swelling under left armpit into left breast area, shoulder and shoulder blade was very sore on left side wrist up to neck back and shoulder blade area felt like a stiff neck, sore to turn head to the left. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events swelling under left armpit into left breast area, shoulder and shoulder blade very sore on left side wrist up to neck back and shoulder blade area feels like a stiff neck sore to turn head to the left. The clinical outcomes of the events swelling under left armpit into left breast area, shoulder and shoulder blade very sore on left side wrist up to neck back and shoulder blade area feels like a stiff neck sore to turn head to the left were not recovered at the time of the report.   No follow-up attempts are needed. No further information is expected
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Lymphadenopathy, Nausea
Clinical narrative: Achy; Nausea; Slight  fever (barely 99); Chills; Exhaustion; swollen lymph nodes of neck; This is a spontaneous report from a contactable consumer, the patient. A 42-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: ER 8730) via an unspecified route of administration in the left arm on 25March2021 at 13:45 as a single dose for COVID-19 immunisation. Patient medical history was kidney stones, long COVID-19 infection. Concomitant medications included clonazepam (MANUFACTURER UNKNOWN), mirtazapine (MANUFACTURER UNKNOWN), vitamins and aluminium hydroxide, magnesium trisilicate, sodium alginate (PEPCID) received within 2 weeks of vaccination. The patient was allergic to dairy and sulfa based antibiotics. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, it was unknown whether patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 27March2021, the patient experienced nausea, slight fever of 99 degree Celsius, chills, exhaustion, swollen lymph nodes in neck, ache. No therapeutic measures were taken for the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events nausea, fever, chills, exhaustion, swollen lymph nodes in neck, ache were unknown at the time of reporting.   No follow-up attempts are possible. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia
Clinical narrative: Achy; Nausea; Slight  fever (barely 99); Chills; Exhaustion; swollen lymph nodes of neck; This is a spontaneous report from a contactable consumer, the patient. A 42-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: ER 8730) via an unspecified route of administration in the left arm on 25March2021 at 13:45 as a single dose for COVID-19 immunisation. Patient medical history was kidney stones, long COVID-19 infection. Concomitant medications included clonazepam (MANUFACTURER UNKNOWN), mirtazapine (MANUFACTURER UNKNOWN), vitamins and aluminium hydroxide, magnesium trisilicate, sodium alginate (PEPCID) received within 2 weeks of vaccination. The patient was allergic to dairy and sulfa based antibiotics. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, it was unknown whether patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 27March2021, the patient experienced nausea, slight fever of 99 degree Celsius, chills, exhaustion, swollen lymph nodes in neck, ache. No therapeutic measures were taken for the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events nausea, fever, chills, exhaustion, swollen lymph nodes in neck, ache were unknown at the time of reporting.   No follow-up attempts are possible. No further information is expected.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: My face itches, Everything under myeyes to my chin. Nose, cheeks, chin; This is a spontaneous report from a contactable other healthcare professional, the patient. A 34-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: En6207) via an unspecified route administration in the left arm on 26Mar2021 at 01:30 (at the age of 34-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as no. There were no known allergies reported. The patient was not on any concomitant medications. The patient had not received any other vaccines within 4 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 27Mar2021 at 10:00, the patient experienced face itches, everything under eyes to chin, it was nose, cheeks and chin, had started the next morning which had lasted all day. The events had not resulted in the visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measure was taken as a result of the adverse events. The clinical outcome of the event itchy was not recovered at the time of report.  No follow-up attempts are needed. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia
Clinical narrative: Muscle ache; Mild fever; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA Vaccine Lot no: EP6955), via an unspecified route of administration in the left arm on 25Mar2021 at 10:15 (at the age of 52-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not have any allergies to medications, food, or other products. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot no: UNKNOWN) via an unspecified route of administration on an unknown date, as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 16:00, the patient experienced muscle ache and mild fever. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events muscle ache and mild fever were recovered at the time of reporting.  No follow-up attempts are possible; information about lot number cannot be obtained.
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal distension, Fatigue, Flatulence, Headache, Myalgia
Clinical narrative: muscle soreness; slight headache; fatigue.; feeling bloated and gas; feeling bloated and gas; This is a spontaneous report from a contactable other healthcare professional, the patient. A 39-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown), via an unspecified route of administration in the left arm on 25Mar2021 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history and known allergies reported as none. The patient did not receive any other medications within 2 weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown), via intramuscular route in the left arm on 28Feb2021 at 14:30 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 25Mar2021 at 16:00, the patient had experienced muscle soreness, slight headache and fatigue. He was feeling bloated and gas since he received the shot which was most significant side effect. At the time of report which was second day and he was still gassy and little pressure in his abdomen but when he passed the gas it went away but then he was geeked with more gas. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events of muscle soreness, slight headache, fatigue, feeling bloated and gas was not resolved at the time of report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Chronic gastritis, Constipation, Mucous stools
Clinical narrative: Ceased Bm's only produced smallamounts that looked like tarry blackrabbit turds; Begin losing intestinallining; sticky mucous; This is a spontaneous report received from a contactable consumer, the patient. A 59-year-old non pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: unknown, Right Arm) via an unspecified route administration on 19Mar2021 at 11:00 AM (at the age of 59-year-old) as a single dose for COVID-19 immunisation. Medical history included as herniated disc or sinus. Patient had allergy with celecoxib(CELEBREX) on unknown date. The patient took  vitamins nos children's chewable vitamins within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient experienced ceased bowel movements and produced small amounts that looked like tarry black rabbit turds, begin to lose intestinal lining, dropped out in chucks as big as two and a half inches long and one inch wide or seeps out in pools of sticky mucous. Patient reported to have to wear a diaper so as to not to make a mess and there was no controlling it. The adverse event resulted in doctor/healthcare/clinic visit. The patient did not received any treatment for the event. The clinical outcome of the events was not recovered at the time of report. No follow-up attempts are possible; information about lot number cannot be obtained.